Immunosuppressive Therapy Optimization: Development of a Population Pharmacokinetic-pharmacodynamic (PK-PD) Model in Liver Transplantation

Immunosuppressive Therapy Optimization: Development of a Population Pharmacokinetic-pharmacodynamic (PK-PD) Model in Liver Transplantation

Prospective, non-randomized, open Pharmacokinetic-Pharmacogenetic-Pharmacodynamic monocentric study. Donor and recipient CYP3A5 genotype and recipient ABCB1 will not be communicate to clinicians or patients during the study.

Inclusion Criteria:

• Adults over 18
• Liver transplant recipients
• Treated with an immunosuppressive protocol with tacrolimus
• Informed on the study and who did not refuse to participate

Exclusion Criteria:

• Patients who participate in a study with procedures incompatible with the present study.
• Patients with legal protection/deprived of liberty.